BioNexus Gene Lab Corp
BGLCNasdaq
$1.66
↑ +0.6%Jul 17 close · end-of-day
Price
1Y↓ -60.9%
End-of-day closes; the latest point is the live 15-min-delayed price · split & dividend adjusted · chart by TradingView
Key statistics
Market Cap
$4.0M
Enterprise Value
$4.0M
P/E
—
P/S
0.8
P/B
0.5
EV/EBITDA
—
PEG
—
FCF Yield
-29.7%
Dividend Yield
—
Revenue (TTM)
$5.3M
Net Income (TTM)
-$2.9M
Free Cash Flow (TTM)
-$1.2M
Gross Margin
14.0%
Operating Margin
-54.4%
Net Margin
-54.7%
ROE
-35.9%
ROIC
-28.2%
Debt / Equity
—
Net Cash
—
Return 1Y
-75.0%
Earnings
BGLC Q1 2026 Earnings
Period ends 2026-03-31
MetricActualYoY
Revenue$22,842.00↓ -98.9%
Diluted EPS-$0.23↓ -35.2%
Actuals from SEC filings; YoY vs the year-ago quarter. Analyst estimates & surprise require a data feed (coming soon).
Financial statements
| Line item | FY2020 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|---|
| Revenue | $11.4M | $13.4M | $10.9M | $9.8M | $9.5M | $7.4M |
| Gross profit | $1.7M | $2.3M | $1.3M | $1.3M | $1.3M | $1.1M |
| Operating income | $1.3M | $1.1M | -$291,177.00 | -$2.6M | -$1.6M | -$3.0M |
| Net income | $1.1M | $751,571.00 | -$355,966.00 | -$2.6M | -$1.6M | -$3.0M |
| Diluted EPS | — | — | — | -$0.17 | -$0.09 | — |
| Operating cash flow | $552,680.00 | $9,161.00 | $551,822.00 | -$1.8M | -$2.1M | -$1.8M |
| Free cash flow | $131,059.00 | $5,999.00 | $551,822.00 | -$2.0M | -$2.3M | -$1.9M |
| Gross margin | 15.1% | 17.0% | 11.5% | 13.6% | 13.6% | 14.6% |
| Operating margin | 11.2% | 7.9% | -2.7% | -26.5% | -16.5% | -39.9% |
| Net margin | 9.6% | 5.6% | -3.3% | -26.9% | -16.8% | -40.2% |
| Line item | Q2 '24 | Q3 '24 | Q4 '24 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 |
|---|---|---|---|---|---|---|---|---|
| Revenue | $2.0M | $2.6M | $2.5M | $2.1M | $2.3M | $2.5M | $483,760.00 | $22,842.00 |
| Gross profit | $288,720.00 | $326,536.00 | $309,234.00 | $343,493.00 | $368,022.00 | $377,685.00 | -$3,983.00 | -$790.00 |
| Operating income | $259,168.00 | -$1.3M | -$416,220.00 | -$618,418.00 | -$611,293.00 | -$702,509.00 | -$1.0M | -$540,490.00 |
| Net income | $199,104.00 | -$1.3M | -$348,319.00 | -$623,327.00 | -$616,172.00 | -$708,991.00 | -$1.0M | -$543,575.00 |
| Diluted EPS | $0.11 | -$0.75 | $0.55 | -$0.35 | -$0.34 | -$0.40 | — | -$0.23 |
| Operating cash flow | -$672,275.00 | -$1.6M | $219,203.00 | -$824,072.00 | -$737,907.00 | -$1.2M | $961,062.00 | -$147,671.00 |
| Free cash flow | -$674,108.00 | -$1.8M | $215,181.00 | -$833,124.00 | -$759,366.00 | -$1.2M | $960,085.00 | -$147,996.00 |
| Gross margin | 14.6% | 12.4% | 12.3% | 16.1% | 16.3% | 14.8% | -0.8% | -3.5% |
| Operating margin | 13.1% | -50.9% | -16.5% | -28.9% | -27.0% | -27.6% | -213.5% | -2366.2% |
| Net margin | 10.1% | -51.1% | -13.8% | -29.2% | -27.3% | -27.9% | -214.2% | -2379.7% |
Company news
Analyst estimates
Coming soonConsensus revenue & EPS estimates and price targets will appear here once a forward-estimates data feed is connected.
Insider transactions
No insider transactions in the last 12 months.
No insider transactions on file.
Fundamentals & filings from SEC EDGAR. Prices adjusted for splits & dividends. Not investment advice.